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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with clinical and etiological heterogeneity and a com-
plex genetic contribution. Clinical, neuropathological, and genetic evidence revealed that ALS and frontotemporal dementia 
(FTD) are in part of a single disease continuum. Genetic causes have been identified in sporadic (SALS) and familial patients 
(FALS) and the recurrent genetic factor underlying ALS and FTD is the C9orf72 hexanucleotide repeat expansion (HRE). 
However, in our population, the concomitance of ALS and FTD cannot be explained by C9orf72 HRE in many FALS and 
SALS cases. Our aim is to further understand the genetic basis of ALS in Portuguese patients. 34 patients with FALS or 
SALS-FTD, negative for C9orf72 HRE, were screened for rare variants in a panel of 29 relevant genes by next-generation 
sequencing. We detected 15 variants in 11 genes, one classified as pathogenic in TARDBP, two as likely pathogenic in 
TARDBP and PRPH, and the others as variants of unknown significance (VUS). Gene variants, including VUS, were found 
in 41.2% FALS patients and 40% SALS-FTD. In most patients, no potential pathogenic variants were found. Our results 
emphasize the need to enhance the efforts to unravel the genetic architecture of ALS-FTD.
Keywords Amyotrophic lateral sclerosis · Frontotemporal dementia · Next-generation sequencing · Genetic screening · 
Gene variants
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult onset, pro-
gressive neurodegenerative disease, characterized by the 
loss of both upper motor neurons (UMN) and lower motor 
neurons (LMN) at spinal cord and bulbar levels. Addition-
ally, cognitive and/or behavioural impairment due to the 
involvement of prefrontal cortex is detected in 30–50% of 
ALS patients, and 13% of patients fulfil the clinical diag-
nostic criteria for frontotemporal dementia (FTD) [1]. Con-
versely, up to 50% of FTD patients develop signs of motor 
involvement with about 15% meeting the diagnostic crite-
ria of ALS [2]. Thus, based on clinical, neuropathological, 
and genetic links, ALS and FTD are now recognized to be 
extremes in the phenotypic spectrum of a single disease: the 
ALS–FTD continuum [1].
Although most ALS patients have sporadic disease, in 
which no family history can be discernible (SALS), the 
population-based rate of familial ALS (FALS) is about 20% 
[3, 4]. In our ALS population, FALS was disclosed in 11.6% 
of patients [5].
Population-based frequency of the mutation rate in ALS 
European populations estimates that variants in four genes 
account for 51% of FALS and 6.2% of SALS, being the 
most common the C9orf72 hexanucleotide repeat expan-
sion (FALS 39.6%, SALS 4.6%), followed by SOD1 (FALS 
6.9%, SALS 0.8%), TARDBP (FALS 2.7%, SALS 0.6%), 
and FUS mutations (FALS 1.8%, SALS 0.2%) [6]. In FTD, 
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the frequency of the C9orf72 expansions in Western Europe 
was about 10%, with 18.5% in familial and 6.3% in sporadic 
FTD patients [7]. Moreover, the C9orf72 HRE accounts for 
up to 88% of familial ALS–FTD patient series and is thus 
the major genetic cause of the FTD–ALS spectrum [8–11]. 
In addition to C9orf72, other genes in ALS/FTD spectrum 
include: CCFN, CHCHD10, CHMP2B, OPTN, SQSTM1, 
TBK1, UBQLN2, and VCP [12, 13].
A large population-based pedigree study confirms that up 
to 50% of variance in ALS has a genetic basis and estimate 
the overall mean lifetime heritability of ALS in C9orf72-
negative patients to be 36.9% (95%CI, 19.8–53.9%) [14]. 
More than 30 genes have been described to confer a higher 
risk for ALS [15–17] and their contribution is complex. ALS 
has a monogenic component of rare high-penetrant variants, 
an oligogenic component of rare intermediate penetrant vari-
ants, and a multifactorial component of common risk vari-
ants, possibly all under the influence of gene–environment 
interactions [18]. A multistep process has been hypothesized 
as necessary for the onset of the disease [19, 20] and the 
number of steps required is reduced in patients with genetic 
variants [21].
We have previously found that, in the Portuguese popula-
tion, C9orf72 HRE accounts for 4.6% of sporadic ALS and 
37.5% of FALS, while SOD1 mutations are rare (0.83%). As 
expected, patients with C9orf72 HRE have a higher preva-
lence of FTD however, but the concomitance of ALS and 
FTD cannot be explained by C9orf72 HRE in 42% of FALS 
and 83% of sporadic cases. Also, two ALS patients with 
FTD onset were C9orf72 HRE negative. Not only a posi-
tive family history for ALS or FTD, but also the presence 
of comorbid FTD increases the chance of having a genetic 
variant by 3.5 [22]. Thus, genetic screening is indicated 
in patients manifesting both diseases without the C9orf72 
HRE, regardless of family history of disease [23, 24].
Thus, whenever possible, our patients with familial ALS 
and/or FTD negative for C9orf72 HRE were investigated 
for rare variants in a panel of ALS genes by next-generation 
sequencing (NGS). Our aim is to further understand the 
genetic basis of ALS in Portuguese patients.
Methodology
Patients
Patients were recruited by MdC in the Neuromuscular Unit, 
Department of Neurosciences, Hospital de Santa Maria-
CHULN, the main ALS center in Portugal. ALS Patients 
met the revised El-Escorial criteria [25], including eligi-
ble patients with PMA (progressive muscular atrophy) and 
PLS (primary lateral sclerosis). Diagnosis was supported 
by neurophysiological evaluation [26]. All included patients 
had disease progression.
Clinical information was recorded following a structured 
assessment tool, incorporating neurological examination 
[27]. FALS was defined based on familial history, and was 
classified as definitive, probable, or possible according to 
the criteria of Byrne and co-workers [28].
The presence of comorbid FTD on clinical judgment 
(always by the same clinician, MdC) was supported by the 
International consensus criteria for possible behavioural 
FTD, i.e., presence of at least three of six clinically dis-
criminating features (disinhibition, apathy/inertia, loss of 
sympathy/empathy, perseverative/compulsive behaviours, 
hyperorality, and dysexecutive neuropsychological profile) 
[29]. The presence of language dysfunction was clinically 
appreciated and selected cases were evaluated by ECAS 
(Edinburgh Cognitive and Behavioural ALS Screen) to con-
firm clinical diagnosis.
The functional rate of decay (ΔFS) was calculated as fol-
lows: (48-total ALSFRS-R at diagnosis)/duration in months 
from weakness onset to diagnosis. We considered the time 
since motor onset, because some patients had previous FTD 
symptoms and the Revised ALS Functional Rating Scale 
(ALSFRS-R) only evaluates motor functional impairment 
[30].
All patients that agreed to be tested and that signed inform 
consent were tested for C9orf72 HRE in GenoMed-Diagnós-
ticos de Medicina Molecular, S.A, as previously described 
[31]. We excluded those with marked signs of respiratory 
insufficiency, and who were psychologically stressed or had 
major depression. From a total of 282 patients tested, 265 
(94%) were negative for C9orf72 HRE (less than 30 GGG 
GCC hexanucleotide repeats in the first intron of C9orf72 
gene).
In the group of 265 C9orf72-negative patients, there were 
19 unrelated FALS patients (7.2% of the total), of which six 
had concomitant FTD, and 23 SALS with concomitant FTD 
(8.7% of the total). From this group, enough DNA quantity 
and quality for further genetic testing with Next-Genera-
tion Sequencing were available from 32 patients (Fig. 1). 
Additionally, two family members with ALS of two FALS 
patients (a brother and a nephew) were also sequenced. All 
patients were Caucasians of European origin (Portugal), 
except for one with African origin.
Targeted gene enrichment and sequencing
Genomic DNA was isolated from whole blood samples 
using a standard in-house salting-out method. Whole-
exome libraries were prepared using the SureSelect Human 
All Exon v6 kit (Agilent). Target regions were sequenced 
(paired-end) on an Illumina platform (NovaSeq 6000) with 
150 base read length, with a medium read depth of at least 
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60x. The exonic and splice-site DNA sequence regions of 
29 ALS relevant genes were analysed in 34 patients, all 
negative for C9orf72: ANG, ATXN2, CCNF, CHCHD10, 
CHMP2B, DCTN1, ERBB4, FIG4, FUS, hnRNPA1, hnRN-
PA2B1, KIF5A, MATR3, NEFH, OPTN, PFN1, PRPH, SIG-
MAR1, SOD1, SQSTM1, SPG11, TARDBP, TBK1, TREM2, 
TRPM7, TUBA4A, UBQLN2, VAPB, and VCP.
In four patients, the following additional genes were 
studied: ALS2, ANXA11, ATP13A2, BSCL2, CHCHD2, 
DAO, ELP3, ERLIN1, EWSR1, GLE1, GLT8D1, GNE, 
GRN, HSBP1, MAPT, NEK1, PLEKHG5, SETX, SLC52A2, 
SLC52A3, TAF15, TIA1, TRPV4, UNC13A, and VRK1. No 
variants were detected in none of them.
The coverage of the gene panel was higher than 98% 
for variants with a read depth of > 20X. Thus, only those 
variants with insufficient quality or coverage are confirmed 
by Sanger sequencing. Genetic analysis was performed at 
GenoMed—Diagnósticos de Medicina Molecular, S.A.
Bioinformatic data analysis
Raw sequencing data in fastq format were assessed for qual-
ity with fastp software (version 0.19.8) and aligned with 
BWA (version 0.7.17) against the human reference genome 
GRCh37.
For variant calling, we used GATK-HaplotypeCaller 
[32] (version 4.1.1.0), FreeBayes [33] (version 1.1.0.46), 
and SAMtools mpileup [34] (version 1.9). While the first 
two apply a haplotype-based approach, the latter use an 
alignment-based approach. By taking advantage of both 
approaches, variants located in coding regions, including 
the splice site, called by at least two of the callers with a 
read depth of 20X or more were selected for further analysis. 
Variants with minor allele frequency (MAF) > 0.01 were fil-
tered out. Reported variants are below the highest disease-
specific maximum credible population allele frequency 
(AF) for which the observed allele count is compatible with 
pathogenicity [35]. AF in control populations and ALS cases 
was determined using variant frequencies from The Genome 
Aggregation Database (gnomAD, version 2.1.1) and from 
project MinE data browser (https ://datab rowse r.proje ctmin 
e.com/) which currently contains WGS data from 4366 ALS 
cases and 1832 controls [36]. Variants were also searched 
at the ALS Data Browser v3, ALSdb, New York City, New 
York (URL: https ://alsdb .org) [date (03, 2020) accessed], 
a catalogue of genetic variants identified from 3317 Cau-
casian ALS patients [37]. The clinical impact of coding 
variants was annotated with the National Center for Bio-
technology Information (NCBI) ClinVar database (https ://
www.ncbi.nlm.nih.gov/clinv ar/) and classified according to 
the American College of Medical Genetics and Genomics 
(ACMG) guidelines [38]. Therefore, synonymous variants 
were reported if computational evidence suggested a pos-
sible impact on splicing [38]. To assess the potential func-
tional consequences of detected variants, we used well-
established computational methods based on evolutionary 
conservation, protein structure, and/or sequence homology: 
MutationTaster [39], PolyPhen-2 HVAR [40], and SIFT 
[41], that predict the effect of the change on protein function; 
the ensemble methods, Combined Annotation Dependent 
Depletion (CADD), Rare Exome Variant Ensemble Learner 
(REVEL) [42], MutationAssessor [43], Meta LR [44], as 
well as conservation scores as computed with the Genomic 
Evolutionary Rate Profiling (GERP) [45]. Thus, the Variant 
Effect Predictor tool (Ensembl.org Release 99) [46] and the 
tools available from the dbNSFP database v3.0 (MetaSVM, 
MetaLR, PROVEAN, SIFT, Polyphen2, MutationTaster, 
MutationAssessor) [47], and LoFtool [48] were used to pre-
dict the effect of each variant on the corresponding protein. 
The probabilities of a variant being splice altering were pre-
dicted with two ensemble learning methods, adaptive boost-
ing (AdaBoost, ada score) and random forests (rf score) [49].
Results
Thirty-two unrelated patients, plus two family members, 
totalizing 34 patients (2 PLS, 7 PMA and 25 ALS) nega-
tive for the presence of C9orf72 HRE and with a positive 
family history for ALS and/or with concomitant FTD were 
analysed with targeted NGS. Thus, considering only unre-
lated patients, 53% were classified as FALS (17/32). The 
studied population consisted of 14 males and 20 females 
with an average age of disease onset of 65.9 ± 13.4 years. 
Fourteen patients had spinal-onset, nine had bulbar-onset, 
one had respiratory-onset, two had a generalized-onset, 
Fig. 1  Schematic diagram with the categorization of the studied 
patients; FALS familial amyotrophic lateral sclerosis, SALS sporadic 
amyotrophic lateral sclerosis, FTD frontotemporal dementia, other 
neurodegenerative disorders include Alzheimer disease, Parkinson 
disease, and FTD and unspecified dementia
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and 8 had FTD-onset. Besides, 13 other patients devel-
oped FTD during disease progression. They all presented 
the behavioural phenotype of FTD, but in a few language 
changes were associated at onset; in most of them, lan-
guage dysfunction was clear over disease progression, as 
identified by abnormalities in writing (agrammatism and 
limited vocabulary). In the patients with milder cognitive 
changes at onset, ECAS confirmed abnormal results, and 
in all patients, cognition deteriorated over disease progres-
sion. Eighteen patients had predominant LMN signs, 15 
had predominant UMN signs, and in one, there was no 
UMN vs. LMN predominance.
The targeted NGS data showed pathogenic variants, 
likely pathogenic variants and those of uncertain signifi-
cance (VUS) in the following 11 genes: CCNF (Cyclin 
F), CHMP2B (Charged Multivesicular Body Protein 2B), 
ERBB4 (Erb-B2 Receptor Tyrosine Kinase 4), FUS (FUS 
RNA Binding Protein), NEFH (Neurofilament Heavy), 
PRPH (Peripherin), SPG11 (Vesicle Trafficking Associated, 
Spatacsin), TARDBP (TAR DNA Binding Protein), TBK1 
(TANK Binding Kinase 1), TREM2 (Triggering Receptor 
Expressed On Myeloid Cells 2), and TRPM7 (Transient 
Receptor Potential Cation Channel Subfamily M Member 7).
The 15 gene variants, including VUS, detected in 13 Cau-
casian unrelated patients are listed in Table 1. All the vari-
ants were found in a heterozygous state.
Based on the American College of Medical Genetics and 
Genomics (ACMG) variant classification, one of the 15 
detected gene variants was categorized as pathogenic, two 
as likely pathogenic and the remaining 12 as VUS.
Three genetic alterations found in our study had already 
been previously reported in ALS: TARDBP (c.1144G > A, 
p.Ala382Thr), a genetic alteration classified as pathogenic, 
that we found in an FALS patient and confirmed its pres-
ence in her affected brother (pedigree 1106). This variant is 
presented in population databases and was found in project 
MinE patients’ dataset but not in controls. This variant has 
been reported in association with both familial and sporadic 
ALS [50].
Also, the likely pathogenic variant in PRPH (c.421G > T, 
p.Asp141Tyr) and the VUS found in FUS (c.1292C > T, 
p.Pro431Leu) have already been described in ALS [51–53]. 
The PRPH gene variant is found in population databases and 
in both ALS patients and controls from project MinE, and 
has conflicting interpretations of pathogenicity at ClinVar 
database. The FUS gene variant is found in population data-
bases but only in ALS patients from project MinE (absent 
in controls) and it is classified as uncertain significance at 
ClinVar database.
Additionally, a novel variant c.1154G > T, (p.Trp385Leu) 
classified as likely pathogenic was found in a mutational 
hotspot for ALS-linked TARDBP variants (exon 6). Another 
variant in the same amino acid (p.Trp385Gly) has already 
been described in ALS [54] and most bioinformatic predic-
tion tools indicate pathogenicity.
Clinical characteristics of patients with pathogenic 
and likely pathogenic variants
The clinical characteristics of patients harbouring gene vari-
ants are presented in Table 2.
Pathogenic and likely pathogenic variants were all found 
in FALS patients. In both pedigrees (1106 and 1363) with 
TARDBP variants, genetic anticipation was observed (i.e., 
appeared at an earlier age in the succeeding generation), 
although disease progression was not more severe, reflected 
in a similar rate of decay and long survival in both cases 
(Table 2). These patients from the second generation were 
not tested with NGS. To note, their disease onset charac-
teristics were similar in sex, age, site, and UMN vs. LMN 
predominance. While #1106 nephew developed FTD after 
long-disease duration, no cognitive alterations were noted 
in #1363 son, who survived long time dependent of non-
invasive ventilation (NIV). Among members of family 1106, 
clinical heterogeneity was observed.
The FALS patient with the PRPH (p.Asp141Tyr) is a 
female with bulbar-onset disease and concomitant FTD and 
LMN predominance.
Variants uncertain significance (VUS)
Variants classified as VUS were found in the following 
genes: NEFH, TRPM7, CHMP2B, ERBB4, TREM2, SPG11, 
and CCNF. Those found in TRPM7, CHMP2B, TBK1, and 
one of NEFH (p.Lys741Gln) are novel variants; absent from 
population databases and from the current dataset of pro-
ject MinE containing WGS data from 4366 ALS cases and 
1832 controls. In silico predictions suggest pathogenicity 
for the TBK1 (c.682C > T, p.Arg228Cys), but are inconclu-
sive regarding the CHMP2B (c.287 T > C, p.Met96Thr), 
and suggest that the NEFH (c.2221A > C, p.Lys741Gln) 
is non-pathogenic. The intronic variant (c.322-2A > C) in 
TRPM7 gene is predicted to be splice altering (ada score: 1; 
rf score: 0.936) and thus pathogenic. The rare variants found 
in CCNF (p.Asn87Lys), both of ERBB4 (p.Phe414Leu) and 
(p.Ile910Val) and one of TREM2 (p.Glu151Lys), are not 
reported in ClinVar database. In silico prediction tools do 
not suggest them to be pathogenic, except for the CCNF. 
In fact, the CCNF (p.Asn87Lys) is presented in patients 
from project MinE, but was not found in controls, though it 
is found in population databases with very low MAF. The 
TREM2 (p.Glu151Lys) is reported in population databases 
as well as in project MinE database. Both TREM2 variants 
(p.Glu151Lys) and (p.Arg47His) have been associated with 
the susceptibility to AD and most bioinformatic predictions 
suggest that they are likely benign. This variant is reported 
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in population databases and in ALSdb with similar frequen-
cies, but is not found in MinE database.
The NEFH (p.Arg352Ser) is presented in both population 
databases as well as in MinE dataset and has conflicting 
interpretations of pathogenicity.
The SPG11 (p.Leu2084Phe) is present in population data-
bases, but was not found in MinE dataset, either in patients 
or controls, or in ALSdb. This variant is reported in Clin-
Var database associated with spastic paraplegia 11, auto-
somal recessive and classified with uncertain significance. 
A potential negative impact is suggested by bioinformat-
ics tools; however, the available evidence is inconclusive. 
Moreover, the conditions related to SPG11 variants are 
inherited in an autosomal recessive pattern and we found it 
in heterozygosity.
The co-occurrence of multiple variants may be under-
estimated in our study, since those patients who were posi-
tive for C9orf72 HRE were not further analysed with the 
NGS gene panel. Nevertheless, three patients harboured two 
rare variants in different genes (8.8%, 3/34): Patient #1106, 
besides the pathogenic TARDBP (p.Ala382Thr) variant, also 
harboured the TREM2 (p.Arg47His) variant. This later VUS 
was not found in her affected brother. Unlike the other family 
members, patient #1106 was the only with bulbar-onset and 
UMN predominance, the oldest at disease onset, and the one 
with the shortest survival (Table 2).
Patient #719 has a novel splice acceptor variant in gene 
TRPM7 and another VUS in gene NEFH (p.Arg352Ser). 
This FALS patient has a very long survival and is still alive.
Patient #1316, who had a VUS in FUS (p.Pro431Leu) 
and another in NEFH (p.Lys741Gln), had late FTD-onset 
disease that after 17 months progressed to the bulbar region.
In the majority of the analysed patients, no potential path-
ogenic variants were found (59.4%, 19/32). Gene variants, 
including VUS, were found in 7 of the 17 FALS patients 
(41.2%) and in 6 of the 15 SALS with concomitant FTD 
(40%). Among those with FTD-onset, VUS were detected 
in 50% (4/8).
Discussion
In our study, we found 15 gene variants in 13 unrelated 
ALS patients negative for C9orf72 HRE, and those variants 
were found in 11 genes: TARDBP, PRPH, SPG11, TRPM7, 
and CHMP2B in FALS patients; ERBB4, FUS, TBK1, and 
CCNF in SALS/FTD patients, and TREM2 and NEFH in 
both SALS/FTD and FALS patients. Nevertheless, in 58.8% 
of FALS and in 60% of SALS/FTD, no variants were identi-
fied in any of the analysed genes. This highlights that efforts, 
like those of project MinE [55], are still needed to identify 
additional genes influencing ALS/FTD risk.
Besides the major ALS genes (C9orf72, SOD1, TAR-
DPB, and FUS), recent extensive genetic screenings of ALS 
patients in European populations have identified variants 
in more rarely mutated genes in only about 4–5% of cases 
[56–59]. Moreover, those results reflect the ALS genetic 
diversity, even among European populations, since those 
variants are found in different genes and not even the major 
ALS genes are found or predominant in all cohorts, except 
the C9orf72 HRE, confirming it as still the main genetic 
cause of ALS/FTD.
We found variants in FUS and TARDBP, but not in 
SOD1, a gene that is rarely found mutated in Portuguese 
ALS patients [5].
Variants classified as pathogenic or likely pathogenic 
were only found in FALS patients in genes TARDBP and 
PRPH.
Both TARDBP variants were found in the mutational 
hotspot in exon 6 [50]. The p.Ala382Thr variant was ini-
tially described in two FALS patients of French origin [60]. 
Subsequently, large studies carried out on patients of Italian 
and French origin have identified this variant in FALS and 
SALS patients with or without FTD (reviewed in [50]). The 
incomplete penetrance of the disease in carriers at 70 years, 
calculated to be 74% in males and 42.5% in females [61], 
justifies why a 73-year-old female from family 1106 (sister 
and mother) is asymptomatic to date. We also found a new 
TARDBP p.Trp385Leu variant that is absent from popula-
tion and ALS datasets; however, another variant in the same 
amino acid, c.1153T > G, p.Trp385Gly, was described in two 
affected brothers, one of which with very long-disease dura-
tion [54]. We found it in a PMA patient with disease onset 
long after his son who survived over 6 years, although for 
more than 2 years fully dependent on Non-Invasive Ventila-
tion (NIV).
Disease anticipation was observed in both families and 
the patients from second generation (#1106 nephew and 
#1363 son) had similar disease onset characteristics. Despite 
that, considerable intrafamilial phenotypic differences in 
age, site of onset, and survival were observed in the fami-
lies carrying the TARDBP variants, as previously reported 
[54], meaning that ALS manifestation is influenced by other 
genetic and environmental factors [62].
PRPH p.Asp141Tyr was the first described variant related 
to ALS in this gene and was found in a homozygous spo-
radic patient with limb onset at 42 years old who died nearly 
3 years after without cognitive changes [52]. It was also 
found in heterozygosity in 4/342 patients and 2/550 controls 
[51, 63]. This variant does not abolish the ability of periph-
erin to assemble into filaments, but leads to the formation 
of aggregates, even in heterozygous state [52]. Although 
this functional evidence upholds that this could be a low 
penetrance variant involved in ALS susceptibility, the excess 
of its frequency in MinE controls and similar frequencies in 
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ALS patients and in population databases argues against it, 
but there is also the possibility of having pre-symptomatic 
individuals in control populations. We found this variant in 
an FALS patient with bulbar-onset disease at 68-years old 
and concomitant FTD that is still alive with almost 4 years 
of disease duration, different from the phenotype previously 
described [52] not confirming a genotype–phenotype rela-
tion for this variant.
In FALS patients, other variants of unknown significance 
were found in genes SPG11, TRPM7, CHMP2B, TREM2, 
and NEFH.
The patient with the SPG11 p.Leu2084Phe missense vari-
ant also had concomitant FTD, a familial history of AD and 
upper limb onset with predominant LMN signs. Although 
SPG11 variants, mainly truncating mutations, have previ-
ously been associated with autosomal recessive juvenile 
ALS [64], several heterozygous missense variants in SPG11 
have been reported in ALS, but attributed to the large size of 
the gene coding region and interpreted as unlikely deleteri-
ous [57, 59, 65–67].
The FALS patients with variants in CHMP2B, TRPM7, 
NEFH, and TREM2 had no signs of FTD. However, vari-
ants in NEFH and TREM2 were also found in SALS/FTD 
patients.
The novel variant in CHMP2B p.Met96Thr was found 
in an FALS patient with late bulbar-onset disease without 
FTD. A variant in the C-terminus of CHMP2B was origi-
nally reported in a Danish pedigree with autosomal domi-
nant FTD [68]. Other variants were later found in ALS and 
PMA in English and Dutch populations, [69, 70] and in one 
Indian SALS patient [71]. We did not find segregation of the 
variant with the disease in the other ALS patient of the fam-
ily, what provides evidence against its pathogenicity.
The TRPM7 (c.322-2a > G) slice acceptor intronic variant 
is predicted to be pathogenic and is not reported in popula-
tion or ALS databases. A missense variant in TRPM7 has 
been described to confer susceptibility to Guamanian ALS 
and Parkinsonian dementia [72]. The discrepancy in TRPM7 
channel function and expression leads to various neuronal 
diseases such as AD and PD. Furthermore, it is a key fac-
tor in anoxic neuronal death and TRPM7 mutations may 
play a crucial role in neurotransmitter release in ALS [73]. 
We found the TRPM7 variant along with a VUS in NEFH 
p.Arg352Ser, in female patient with very long-disease sur-
vival (92.6 months, still alive) and whose father had ALS 
and mother had AD.
Neither NEFH variants were described in ALS; in fact, 
the p.Lys741Gln is a new variant not reported in population 
databases, but predicted to be likely benign by bioinfor-
matic tools. Previously described clinical features observed 
in individuals with the NEFH (c.1054C > A, p.Arg352Ser) 
variant include: hypertonia, abnormality of coordina-
tion, morphological abnormality of the central nervous 
system, and neurophysiological changes (NCBI. ClinVar; 
[VCV000066725.3], https ://www.ncbi.nlm.nih.gov/clinv ar/
varia tion/VCV00 00667 25.3 (accessed Feb. 20, 2020).
Further studies are needed to conclude about the patho-
genicity of the detected VUS. Both were detected in patients 
who also had another variant. The NEFH p.Arg352Ser was 
detected along with the TRPM7 c.322-2A > G in an FALS 
patient with very long survival. The NEFH p.Lys741Gln 
was found in a patient with FTD-onset that also harboured 
a variant in FUS p.Pro431Gln.
TREM2 gene variants were reported to increase the risk 
of AD and other neurodegenerative diseases [74]. Recent 
meta-analysis studies have confirmed TREM2 p.Arg47His 
to be significantly associated with AD and PD risk in North 
Americans, but not PD in Europeans or ALS [74] and to be 
gene a risk factor for FTD in Caucasian populations [75]. 
The TREM2 p.Arg47His variant has also been associated 
with a neuroinflammatory processes, especially microglial 
activation [76, 77].
The TREM2 p.Glu151Lys was described before as risk 
factor for AD [78] and was found in a demented patient 
with LMN signs and Parkinsonism who was positive for the 
C9orf72 HRE [79]. We detected the TREM2 p.Glu151Lys 
variant in patients with late-onset disease (above the age of 
80), one of which was a PMA patient with positive familial 
history, and the other was an SALS/FTD patient with UMN 
predominance and very short survival. The FALS patient 
with the TREM2 p.Arg47His variant also harboured the 
pathogenic TARDBP p.Ala382Thr, but in her brother, the 
TREM2 variant was not detected. The diverse neurodegen-
erative phenotypes associated with TREM2 variants indicate 
a role in neurodegeneration, although its risk effect in ALS 
remains elusive.
In the sporadic patients with FTD-onset, we found vari-
ants in genes FUS, TBK1, CCNF and ERBB4.
Since 2009, when the first FUS mutations were associ-
ated with ALS [80, 81], more than 50 variants have been 
identified in this gene [50, 82] with a frequency in European 
populations of about 2.8% in FALS and 0.3% in SALS [6]. 
Most pathogenic FUS variants are located in the C-termi-
nal within, or completely deleting, the nuclear localization 
signal, thereby impairing nuclear import of FUS [83]. We 
found a variant at the zinc-finger motif, a rarely mutated site 
that has a predominant role in RNA recognition [84, 85]. 
This variant was first described in a patient with hereditary 
essential tremor-4 (ETM4; 614,782) whose lymphoblastoid 
cells showed lower expression of mutant FUS mRNA than 
did cells from patients with ALS due to FUS variants [86]. 
It was later found in an SALS Caucasian male patient with 
spinal-onset at the age of 60 [53], a quite different phe-
notype from our patient: a 75-year-old female with FTD-
onset that evolved to the bulbar region after 17 months. It 
is known that certain FUS genetic variants do result in very 
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different phenotypes [83, 87] emphasizing the influence of 
other factors in disease manifestation which, in this case, 
could be related with the presence of the NEFH variant 
p.(Lys741Gln), even if it is predicted to be likely benign. 
Also, the lack of significant numbers of non-nuclear locali-
zation signal variants preclude the description of their phe-
notypes properly [83]. FUS mutation carriers usually mani-
fest earlier symptom onset, a higher rate of bulbar-onset, and 
shorter disease duration. Nonetheless, FTD has rarely been 
reported among ALS patients with FUS variants [87–89].
Whole-exome sequencing and a gene-based rare vari-
ant analysis identified TBK1 as an ALS gene [37, 90]. In 
ALS–FTD patients, most reported pathogenic TBK1 variants 
are loss-of-function (LoF) mutations [90–92] and functional 
TBK1 missense variants have been proposed to be consid-
ered high risk rather than causal variants [92]. However, 
in vitro tests have demonstrated that at least some missense 
variants have functional deficits and, therefore, may be dis-
ease‐causing [90, 93]. Furthermore, a recent meta-analysis 
has shown that LoF mutations are less frequent than mis-
sense variants in ALS–FTD and both are associated with 
an increased risk for ALS–FTD spectrum. However, while 
TBK1 LoF mutations were associated with a significant 
increased risk, missense variants of TBK1 were only related 
to a moderately increased susceptibility [94]. We found a 
missense variant predicted to be pathogenic by in silico tools 
in a patient with FTD-onset that progressed to lower limbs 
1 year after and whose father had PD.
CCNF was found as ALS causative gene in a genome-
wide linkage analysis in large ALS–FTD kindred [95]. The 
analysis of a replication cohort suggested its role in both 
FALS and SALS pathogenesis through abnormal ubiquit-
ination and accumulation of ubiquitinated proteins, includ-
ing TDP-43 [95]. We found a rare variant, predicted to be 
pathogenic, in an SALS patient with FTD-onset disease that 
progressed to the bulbar region after 8 months and whose 
mother had AD/dementia.
Rare genetic variants in the ERBB4, a member of the epi-
dermal growth factor subfamily of receptor tyrosine kinases, 
were detected in different pedigrees of FALS patients by 
whole-genome sequencing and parametric linkage analysis 
[96]. Clinical presentations of those individuals were charac-
terized by the involvement of both UMN and LMN, a lack of 
obvious cognitive dysfunction, and relatively slow progres-
sion. ERBB4 variants were later found in patients with ALS 
with concomitant FTD [23, 97] some evidencing incomplete 
penetrance [97]. Both our patients with ERBB4 variants had 
UMN predominance and concomitant FTD; one of them 
presented with FTD 4 years before upper limb symptoms. 
No familial history of ALS or any other neurodegenerative 
disease was uncovered.
Although both found variants are rare and in silico pre-
dictions are inconclusive, p.Ile910Val is located within the 
tyrosine kinase domain and p.Phe414Leu within a receptor 
domain, suggesting that these variants might impact recep-
tor ligand interaction and kinase activity, key functions of 
ErbB4.
In summary, regarding the VUS found in FUS, SPG11, 
TRPM7, TBK1, CCNF, ERBB4, NEFH, and TREM2, no defi-
nite conclusion regarding its pathogenicity can be drawn 
and further functional, genetic, and clinical studies in large 
independent cohorts, which are required to fully understand 
and establish their contribution for ALS.
In agreement with several studies that have shown an oli-
gogenic basis of ALS [12, 53, 57, 98–100] as the number 
of patients with multiple ALS-associated variants is higher 
than what can be expected by chance, based on the indi-
vidual mutation frequencies of the respective genes, we also 
found three patients carrying two potential disease-causing 
variants. Thus, certain variants alone may not cause disease 
and the simultaneous analysis of disease genes is highly 
important [59].
For those variants that had already been described in 
ALS, we observed some consistency of phenotypes with 
those previously reported, supporting possible geno-
type–phenotype relation, but mainly, we found distinctive 
characteristics highlighting the influence of other genetic 
and non-genetic factors in ALS manifestation.
A recent population-based parent–offspring heritability 
study showed that inherited and non-inherited factors con-
tribute approximately equally toward ALS, and that even in a 
population devoid of known gene mutations, genetic factors 
account for almost 40% of the risk [14].
All the above emphasize the need to continue and enhance 
the efforts to unravel the genetic architecture of ALS-FTD 
mindful that only a better knowledge of the disease will give 
us the basis to fight it.
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